ESPE Abstracts

ESPE Abstracts

Published by BioScientifica
Previous issue | Volume 92 | ESPE2019 | Next issue

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

Card image cap
The theme of this year’s meeting is Variety and Variation in Paediatric Endocrinology. Join us in Vienna to explore the diversity we encounter in our discipline and the care that we have to exercise when using the term “normality”. Whilst gaining an update on the latest treatments, clinical best practice and cutting edge research in the field of paediatric endocrinology.

Poster Category 2

GH and IGFs

Previous section
Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia)
Table of contents
Next section
Growth and Syndromes (to include Turner Syndrome)

hrp0092p2-153 | GH and IGFs | ESPE2019

Criteria for First-Year Growth Response to Growth Hormone Treatment in Prepubertal Children with Growth Hormone Deficiency: Do they Predict Final Height Outcome?

Straetemans Saartje , De Schepper Jean , Thomas Muriel , Tenoutasse Sylvie , Beauloye Véronique , Rooman Raoul , BESPEED the members of

Background/Aim: Several criteria for the first year growth response (FYGR) to growth hormone (GH) treatment have been proposed. We explored which FYGR criteria predict best the final height outcome after GH treatment in prepubertal children with GH deficiency (GHD).Methods: Height data of 129 GHD children (83 boys) treated with GH for at least 4 consecutive years with at least 1 year before pubertal onset, were retrieved...
0 shares

hrp0092p2-154 | GH and IGFs | ESPE2019

Determinants of the Peak GH Response of the Glucagon Stimulation Test in Slowly Growing Children

De Schepper Jean , Dewulf Charline , Craen Marghareta , Cools Martine , Gies Inge

Background/Aim: Currently, the minimum of the GH peak (pGH) to GH provocative stimuli, including the glucagon stimulation test (GST), has been arbitrary set in children at 7 µg/L, irrespective of gender and age. Several doses (fixed or per bodyweight) and ways of administration (IM or SC) of glucagon are being used in daily practice. This retrospective study explores the influence of gender, age, and adiposity on the pGH after a maximally effective glucag...
0 shares

hrp0092p2-155 | GH and IGFs | ESPE2019

First Reported Egyptian Sibs with the Rare Laron Syndrome

Nabil Khalaf Amira

Laron's syndrome, or Laron-type dwarfism, is an autosomal recessive disorder characterized by an insensitivity to growth hormone.There are exceptionally low levels of insulin-like growth factor (IGF-1)caused by homozygous or compound heterozygous mutation in the growth hormone receptor gene .It causes severe short stature and can be treated with injections of recombinant IGF-1. Laron syndrome is a rare disorder. About 350 people have been diagnosed with the condition world...
0 shares

hrp0092p2-156 | GH and IGFs | ESPE2019

Growth Hormone Monotherapy Versus Combined GH and LHRH Analog in 2 Sisters with Short Stature, Early Pubertal Development, and Advanced Bone Age (BA)

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed

Introduction: There is still a debate on the effect of combined treatment with growth hormone (GH) and a luteinizing hormone-releasing hormone (LHRH) analog versus GH alone on final adult height in children with idiopathic short stature (ISS) and those who have early pubertal development at a short height.Case Report: We studied two sisters with a history of familial short stature, early puberty and advanced bone age at ...
0 shares

hrp0092p2-157 | GH and IGFs | ESPE2019

Long-Term Follow-Up of Three Patients with Isolated Growth Hormone Deficiency Type IA Withsustained Growth Response to rhGH

Makretskaya Nina , Babinskaya Svetlana , Chikulaeva Olga , Tiulpakov Anatoly

Background: Isolated growth hormone deficiency type IA (IGHD IA) is described in families with homozygous GH1 deletions that arise from unequal recombination and crossing over within the GH gene cluster during meiosis. Patients with IGHD IA show early and severe growth failure and tend to develop antibodies upon treatment with recombinant human growth hormone (rhGH).Aims: To present the follow−up of three ...
0 shares

hrp0092p2-158 | GH and IGFs | ESPE2019

Clinical and Genetic Characteristics of Eleven Korean Patients with Hypochondroplasia and Outcomes of Growth Hormone Therapy

Kim Min-Sun , Im Minji , Park Hyojung , Park Mi Jung , Kim Shin Hye , Cho Sung Yoon , Jin Dong-Kyu

Hypochondroplasia (HCH) is an autosomal dominant inherited skeletal dysplasia with abnormal growth pattern and inadequate pubertal growth spurt. Achondroplasia and HCH have many similar phenotype, however, HCH show the mildest phenotype among FGFR3-associated skeletal dysplasia, and the radiologic findings are usually so subtle. We investigated to evaluate clue for the hypochondroplasia, and clinical and genetic characteristics of eleven Korean patients with HCH. We a...
0 shares

hrp0092p2-159 | GH and IGFs | ESPE2019

Growth Hormone Treatment Adherence in Latin American Patients: 2-Year Real World Data from the Easypod™ Connect eHealth Platform

Restrepo Manuela , Koledova Ekaterina , Tornicasa Vincenzo

The easypod™ injection device allows automatic recording and transmission of adherence data from patients receiving recombinant human growth hormone (r-hGH; Saizen) to treat growth disorders. Through the easypod™ connect platform, healthcare professionals can access transmitted data and gain insights into adherence patterns. This analysis aimed to evaluate real-world adherence to r-hGH therapy administered via easypod™ at 1, 3, 6 12 and 24 months, plus overall d...
0 shares

hrp0092p2-160 | GH and IGFs | ESPE2019

Metabolic Outcome in Adolescents with Growth Hormone Deficiency During Transition Phase

Improda Nicola , Moracas Cristina , Paolo Ciccarelli Gian , Capalbo Donatella , Salerno Mariacarolina

Background: It is well known that GH deficiency (GHD) in adulthood is associated with detrimental cardiovascular (CV) effects. Although data are controversial, adolescents with childhood-onset GHD (COGHD) and reconfirmed GHD may have increased metabolic risk after GH treatment withdrawal at final height (FH).Aim: Aim of our study is to compare growth response and metabolic profile in idiopathic COGHD adolescents with rec...
0 shares

hrp0092p2-161 | GH and IGFs | ESPE2019

The Influence of Pituitary MRI Findings on Clinical Presentation and Growth in GH-Treated Children with Congenital Hypopituitarism

Adel Djermane , Asmahane Ladjouze , Yasmine Ouarezki , Kahina Mohamedi , Hassina Benlarbi , Samira Aggoune , Zahir Bouzrar , Hachemi Maouche

Introduction: MRI imaging is the technique of choice in the diagnosis of children with hypopituitarism. Marked differences in MRI pituitary gland morphology suggest different etiologies of GHD, different clinical and endocrine outcome and different prognoses.Objective: To investigate the auxological, clinical and hypothalamic pituitary-MRI features in children with non-acquired growth hormone deficiency (GHD); and determ...
0 shares

hrp0092p2-162 | GH and IGFs | ESPE2019

Metabolic Effects of Growth Hormone Treatment in Short Prepubertal Children: A Double-Blinded Randomized Clinical Trial

Tidblad Anders , Gustafsson Jan , Marcus Claude , Ritzén Martin , Ekström Klas

Objective: Growth hormone (GH) is a central hormone for regulating linear growth during childhood and also highly involved in metabolism of lipids, carbohydrates and protein. However, few studies report on how treatment with GH during childhood influences metabolic parameters. Our aim was to investigate metabolic effects of different doses of GH in short children with GH peak levels in the low normal range.Design: Thirty...
0 shares

hrp0092p2-163 | GH and IGFs | ESPE2019

Growth Response in Short Preterm- Born Children Small for Gestational Age in First Year of Growth Hormone Treatment

Korpal-Szczyrska Maria , Szczyrski Jan , Mysliwiec Malgorzata

Background: Growth hormone (rGH) treatment is an approved growth promoting therapy in children born small for gestational age (SGA) without spontaneous catch-up. SGA infants may be born either full-term or premature. Prematurity is an additional risk factor for adult short stature. Premature children born SGA may potentially be affected by combination of the effects of prematurity and SGA status. There are only few reports on premature SGA children treated wit...
0 shares

hrp0092p2-164 | GH and IGFs | ESPE2019

Brain Magnetic Resonance Imaging in Children with Isolated Growth Hormone Deficiency and Idiopathic Short Stature Diagnoses

Yesquen Pamela , Clemente María , Campos Ariadna , Mogas Eduard , Vázquez Élida , Carrascosa Antonio , Yeste Diego

Introduction: Diagnosis of growth hormone deficiency (GHD) and idiopathic short stature (ISS) is not straightforward. Nowadays growth hormone (GH) stimulation tests play a key role in the diagnosis but they are controversial due to the lack of normative data, poor reproducibility and poor disease concordance.The magnetic resonance imaging (MRI) is also a tool in the study of patients with short stature. Structural alterations of the hypo...
0 shares

hrp0092p2-165 | GH and IGFs | ESPE2019

The Clinical Significance of Post-Sleep Growth Hormone Levels in the Diagnosis of Growth Hormone Deficiency

Yoo Chaeri , Kyung Mo , Yoo Eun-Gyong

Background: The growth hormone (GH) stimulation test, which requires multiple blood sampling, should be performed to confirm the diagnosis of growth hormone deficiency because of the pulsatile secretion of GH. In addition to hypoglycemia, L-dopa and arginine, deep sleep is also known as an important stimulator of GH secretion.Objectives: The aim of study was to assess the accuracy and predictive value of the test of post...
0 shares

hrp0092p2-166 | GH and IGFs | ESPE2019

Prediction of the First-Year Response to Growth Hormone Treatment in Prepubertal Korean Children with Idiopathic Growth Hormone Deficiency: Analysis of Data from the LG Growth Study Database

Cho Wonkyoung , Ahn Moon-Bae , Cho Kyoung Soon , Jung Min Ho , Suh Byung-Kyu

Background: Insufficient data exist for the prediction of the first-year response to growth hormone (GH) treatment in Korean prepubertal children with idiopathic GH deficiency (GHD).Methods: Data from children (n = 345) who were in the LG Growth Study Database or had participated in other relevant clinical trials were used to develop a model. All included patients had been diagnosed with idiopathic GHD with maximum G...
0 shares

hrp0092p2-167 | GH and IGFs | ESPE2019

Adherence and Long-Term Outcomes of Therapy in Pediatric Subjects in Argentina using Easypod™ Electromechanical Device for Growth Hormone Treatment: The Phase IV Multicentre Easypod™ Connect Observational Study (ECOS)

Chareca Cinthia D , Belgorosky Alicia , Chiarpenello Javier , Colombi Lia , Pasqualini Titania , Von Schulz Hausmann Cristian , Assefi Aria , miras mirta

The Easypod™ Connect Observational Study (ECOS) assessed real-time adherence in patients from 24 countries who were receiving recombinant human growth hormone (r-hGH; Saizen®) via easypod™, which is an electronic injection device. Overall, ECOS showed mean adherence was maintained at ~80% for up to 3 years. Here, we assess the adherence to r-hGH administered via easypod™ in the Argentinian cohort of patients from ECOS (NCT01582334).<p class="ab...
0 shares

hrp0092p2-168 | GH and IGFs | ESPE2019

...
0 shares

hrp0092p2-169 | GH and IGFs | ESPE2019

Experience of Growth Hormone Therapy in Two Cases with Congenital Adrenal Hypoplasia

Suman Gök Ebru , Direk Gül , Uzan Tatli Zeynep , Akin Leyla , Hatipoglu Nihal , Kendirci Mustafa , Kurtoglu Selim

Introduction: DAX1 (NROB1) mutation, that is among the causes of primary adrenal insufficiency; is revealed with X-linked congenital adrenal hypoplasia and hypogonodotropic hypogonadism. Growth hormone (GH) deficiency is not common in affected individuals. In the literature, there are few cases of GH treatment . growth hormone therapy in two cases with DAX1 gene mutation were evaluated in clinical features and treatment responses.<strong...
0 shares

hrp0092p2-170 | GH and IGFs | ESPE2019

Growth Hormone Therapy in Patients with SGA Short Stature Improves Body Composition by Increasing Muscle Mass and Bone Mineral Density Rather Than Decreasing Fat Mass

Maeyama Takatoshi , Ida Shinobu , Shoji Yasuko , Etani Yuri , Kawai Masanobu

Background: Children born SGA have been implicated to be at higher risk for subsequent obesity; however, the body composition, especially fat distribution, in SGS short stature (SGA-SS) patients and the effects of growth hormone (GH) therapy on body composition in SGA-SS have not been fully studied.Purpose: To unravel the effects of GH therapy on body fat mass, body fat distribution, muscle mass, and bone mineral density...
0 shares

hrp0092p2-171 | GH and IGFs | ESPE2019

Final Height in GH-deficient Paediatric Patients: A Nationwide Experience

Zucchini Stefano , Lonero Antonella , Bellone Simonetta , Bozzola Mauro , Cassio Alessandra , Felicia Faienza Maria , Giacomozzi Claudio , Grandone Anna , Guzzetti Chiara , Iughetti Lorenzo , Parpagnoli Maria , Salerno Mariacarolina , Elizabeth Street Maria , Tornese Gianluca , Wasniewska Malgorzata , Delvecchio Maurizio

Background: The primary goal of GH treatment in GHD children and adolescents is to normalize height, in order to attain an adult height within the target height (TH) range.Aim: to investigate height improvement in GHD paediatric patients treated with GH in our Country.Subjects: 737 patients with isolated GHD (39.5% females) from 13 tertiary Centres for Paediatric Endocrine Care...
0 shares

hrp0092p2-172 | GH and IGFs | ESPE2019

Differences of Efficiency of Treatment of Isolated Growth Hormone Deficiency and Panhypopituitarism in Children in Real Clinical Practice

Rudkova Ekaterina , Grisuk Ivan , Solntseva Angelica

Introduction: Deficiency of growth hormone (GH) in children is manifested by pronounced stunting (below -2 sigmal abnormalities (SD)). Frequency of occurrence varies from 1:4000 to 1:10000 newborns.Objective: To assess the effectiveness of treatment by comparing the dynamics of growth of children with isolated growth hormone deficiency (IGHD) and of children with panhypopituitarism (PHP).Ma...
0 shares

hrp0092p2-173 | GH and IGFs | ESPE2019

Implementation of a Growth Disorders Related Twinning Program in Pediatric Endocrinology – is it Necessary and Feasible?

Halvadzhiyan Irina , Iotova Violeta , Galcheva Sonya , Petrova Chaika

Background: Currently, only two centers for diagnosis and treatment of growth disorders are operating in the Western and Eastern parts of Bulgaria. About 200 children are currently GH treated while at least as many children with growth disorders from mostly Central Northern and Southern Bulgaria are presumably not diagnosed. Thus inequalities in children's access to health care are created. In order to correct this and to quickly align practices between ex...
0 shares

hrp0092p2-174 | GH and IGFs | ESPE2019

Empirical Change of Practice in Treatment of Growth Hormone Deficient Patients in Order to Improve 1st Year Height Outcome

Rankova Kamelia , Galcheva Sonya , Mladenov Vilchelm , Boyadzhiev Veselin , Bocheva Yana , Yordanova Nikolinka , Bazdarska Yulia , Iotova Violeta

Growth hormone (GH) has been used for the treatment of short stature due to GH deficiency (GHD) for over 60 years. Height velocity (HV) in the first year of therapy is well studied and its crucial importance for growth outcome in subsequent years is confirmed.Objectives: The aim of this study is to assess the responsiveness to GH treatment in GHD patients of a newly established treatment center before and after change in starting GH dose...
0 shares

Published by BioScientifica

ESPE Abstracts

© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more